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Abstract

Oxidative stress contributes to the degeneration of retinal pigment epithelial (RPE)
cells and photoreceptors that lead to the dry form of age-related macular degeneration.
Activation of N-Methyl-D-aspartate (NMDA) receptors contributes to the increase of free
radicals that induce oxidative stress-induced changes. Our study investigates if
Dextromethorphan, an NMDA receptor antagonist, reverses oxidative stress-induced
changes in RPE. We used Paraquat and H2O2 as oxidative stress-inducing agents to
induce oxidative damage in human ARPE-19 cells. To illustrate the change in cell viability
and measure the apoptosis of ARPE-19 cells from oxidative damage, we performed MTT
assay and Annexin V-DAPI flow cytometry analysis. Total RNA and protein from the
treated and control samples were analyzed by reverse transcriptase PCR (RT-PCR) to
evaluate changes in genes responsible for cell protection and inflammation. The MTT
(n=6) and flow cytometry assays (n=3) demonstrated significant cell viability compared to
the control cells (p< 0.05) treated H2O2 (400μM) induced oxidative stress. RT-PCR
analysis showed induction of protective antioxidant genes (GCLM, GSTM1, NQO1,
NRF2, MT1, SOD2) and reduced inflammatory genes (IL1β, IFNy, IL-17, MCP1, TNFα)
in response to Dextromethorphan treatment under oxidative stress in ARPE-19 cells. The
current findings suggest that dextromethorphan plays a protective role in RPE by
mitigating oxidative stress-induced change.
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Chapter 1
Introduction

1.1 Anatomy and Function of Human’s Retina
The retina of the eye is a photo-sensitive layer that lines the interior part of the
posterior eye’s segment. It is comprised of two layers, the first layer is the neuroretina
that has photoreceptors, neurons, and ganglions; and the second layer is the retinal
pigment epithelium (RPE). These two layers are separated by a region that is referred to
as the subretinal space. Neuroretina is responsible for the conversion of light into a neural
signal, and its inner parts are supplied by the central retinal artery [1]. Retinal Pigment
Epithelium (RPE) is a continuous monolayer of cells in the eye that is placed between the
retinal photoreceptors and choroidal capillaries and contoured by Bruch’s membrane
(BM). Choroidal capillaries branch from the posterior ciliary arteries and it supplies RPE,
photoreceptors, and the outer part of the neuroretina with oxygen and nutrients [2].
Bruch’s membrane (BM) that lies between the choroidal capillaries and RPE is made of
elastin and collagen and acts as an integral wall that prevents the invasion of choroidal
vessels into the retina [3].

Generally, mature RPE cells are generated from the retinal peripheral part, then
proliferate and migrate to the retinal central part. RPE has several functions in the eye

1

such as the formation of the blood-retinal barrier, keeping ionic homoeostasis by
preventing the leakage of extracellular fluid coming from choriocapillaris into the
subretinal space, and it also prevents the accumulation of immune cells across the bloodretinal barrier (BRB)[2]. RPE also helps in the turnover process of photoreceptors by
lysosomal degradation and phagocytosis mechanisms. Moreover, it is involved in other
functions such as protecting the retina from oxidative stress, delivering nutrients to the
eye, disposing of wastes, synthesizing and releasing growth factors, and initiating ocular
immune responses. That is in addition to the re-isomerization of all-trans-retinal [4] which
is an essential intermediate of the visual cycle that is vital for the regeneration of lightsensitive visual pigments and photoreceptors survival in the retina [5]. The tight junctions
between RPE cells serve as a protecting layer for the neuroretina from toxins in blood
circulation and the RPE’s pigments act as light-absorbents, protecting the eye from the
light-oxidative damage [4]. In the retina, there is an area that measures around 5.5 mm,
and referred to as ‘macula’ or ‘macula lutea’, this area is highly responsible for the central
vision, visual acuity, and providing eyes with their highest resolving power. It is different
from the retina’s peripheral part in structure as it has multiple neuronal layers called retinal
ganglion cells that function as visual inputs’ transmitters to the visual parts of the brain
[6]. The degeneration of the macula along with aging is the pathophysiological condition
that is known as age-related macular degeneration (AMD) that can be clinically diagnosed
by direct or indirect ophthalmology, which is confirmed by different imaging modalities.

2

Figure 1.1 Structure of (A) the normal eye and (B) the normal retina. Permission
received [7].
1.2 Age- related macular degeneration (AMD) Statistics
Age-related macular degeneration (AMD) is a progressive degenerative disease
that affects the macular region of the retina and causes loss of central vision [8]. It is a
leading cause of permanent blindness in the old-age population and is ranked the third
after cataract and glaucoma. AMD has affected 30 million people globally and is expected
to affect 300 million persons in 2040 [9]. AMD incidence starts to increase after the age
of 55, is more common in the age of 75 years and older, and has been reported to be
more prevalent in developed countries [10]. Therefore, AMD is posing a considerable
public health problem with increased socioeconomic burdens [9].
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1.3 AMD categorization and risk factors
Age-related macular degeneration (AMD) is categorized into two stages based on
the clinical presentation of the retinal macula. Early-stage AMD is referred to as dry AMD
or geographic atrophy, where yellow lipid deposits ‘Drusen’ accumulate under the retina
and the retinal pigment epithelium integrity becomes irregular, resulting in reduced visual
acuity. Late-stage AMD and wet AMD are characterized by either macular atrophy or
choroidal neovascularization, and both severely affect central vision. In macular or
geographic atrophy, loss of vision occurs as a result of the macular drop out of RPE and
photoreceptors, while in wet AMD or neovascular exudative AMD that account for 80% of
cases of blindness, RPE is invaded by abnormal blood vessels that are generated by the
choroid and referred to as choroidal neovascularization (CNV) [11], [12].

Although AMD pathogenesis is complicated and not completely understood,
multiple risk factors are directly associated with the progression of the disease such as
aging, family history, and genetic mutations, smoking, and environmental and clinical risk
factors [13]. Advancing in age induces several physiological retinal changes, including
reduced nµmber and function of RPE, ganglion cells, and photoreceptor cells [14]. That
is in addition to the increased thickness of the Bruch’s membrane (BM) and its
biochemical irregularities that lead to RPE- cell layer impaired function [15], [16].
Furthermore, it has been found that aging has a direct correlation with the intensified RPE
oxidative damage, and disrupted retinal immunological responses, leading to further
retinal injury [13]. Oxygen is the most essential oxidant to be utilized by the mitochondrial
oxidative metabolism of the organic molecules in different body organelles including the
4

retina to generate cellular energy. During these oxidative metabolic reactions in the retina,
the oxygen might be partially reduced and result in by-products that are referred to as
reactive oxygen species (ROS) such as superoxide anion (O2), hydrogen peroxide (H2O2)
and, hydroxyl (OH) radicals, and the condition of the high production of ROS is termed as
oxidative stress [17]. In normal situations, retinal cells can attain a homeostatic state
under OS conditions; however, when an imbalance between the pro-oxidative and antioxidative signaling occurs, OS then results in the disruption of retinal structure and
function, leading to nµmerous retinal diseases such as glaucoma, age-related macular
degeneration (AMD), diabetic retinopathy, and retinitis pigmentosa (RP) [18].

In addition to aging, positive family history and genetic mutations play a major role
in AMD pathogenesis. AMD is associated with several single- nucleotide polymorphisms
(SNPs) in the genes that are responsible for the regulation of complement pathways and
immune responses regulation in RPE [19] that will be further discussed. Smoking is
considered a serious risk factor for the severe progression of AMD and has been reported
to increase the risk of AMD in people with genetic mutation by two- to three-fold [20].
Besides, smoking leads to a worsened response of the eye to anti-VEGF therapy in wet
AMD patients [21]. The correlation between smoking and AMD progression is not fully
interpreted; nevertheless, some studies report that smoking may limit choroidal blood
flow, resulting in ischemia and infarction of the retinal tissues and macular degeneration
[22]. Further studies have also shown that smoking decreases the optical density of the
macular pigment that serves as a macular protective layer from [23].

Clinical and

environmental factors such as constant light exposure, medical history of cataract
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surgeries, metabolic syndrome, and low anti-oxidant diet have been reported to hold a
major risk for developing AMD [22-24].

1.4 AMD Pathogenesis
In addition to the genetic predisposition of AMD, there are generally four processes
that have been reported to lead to the development and progression of the two types of
AMD, the dry and the wet forms. These processes include the lipofuscinogenesis,
drusogenesis, inflammation, and neovascularization. The mutations in genes like (SOD2,
APOE, FIBL-6, ABCA4, and others) have been correlated to the development of AMD,
and recently (Y402H), which is a common variant of the complement factor H (CFH) gene
have been also reported to contribute to 50% of AMD morbidities [25]. Several AMD
treatments options such as intravitreal anti-vascular endothelial growth factor (VEGF)
injections and anti-oxidant drugs have been developed; however, these injections have
several complications, and current research is focusing on the development of longlasting treatments for neovascular AMD and promising prophylactic therapies to slow
down the progression of geographic atrophy [26]. Reactive oxygen species (ROS) are
free radicals that are normally produced as a result of metabolism in cells, and they are
detoxified through intracellular and extracellular mechanisms. The dysfunction of those
protective mechanisms or the presence of factors that induce oxidative stress contributes
to many diseases; especially neurodegenerative diseases. There have been several
efforts to address the role of oxidative stress in the development of retinal degenerative
diseases such as glaucoma, diabetic retinopathy, and age-related macular degeneration
(AMD). After the cellular injury, during post-ischemic conditions or aging, the cellular
6

redox equilibrium system gets impaired and subsequently, the cell survival signals are
inhibited which lead to cell death [27] The mitochondrial oxidizing glutamate [28],
prolonged retinal excitation by light [29,30] hyperactivity of nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase after bacterial and fungal infections [31], and
the increase of Xanthine oxidase post-ischemia or in nutrient starvation conditions have
proven to be major causes of oxidative stress formation in the retina that lead to Retinal
pigment epithelium (RPE) angiogenesis and phagocytosis [32].

1.5 Role of Glutamate Receptor in Cell Death
Several studies have reported the excitatory effects of glutamate amino acid in the
brain, the eye, and different organs and its excitotoxic effects when it accumulates
extracellularly and overstimulates glutamine receptors. The overexpression of glutamine
receptor leads to the production of oxygen and nitrogen reactive species that induce
oxidative stress and result in cell and neural damage. Under certain conditions, highaffinity glutamate transporter proteins can remove the excess extracellular glutamate and
protect cells. Also, the elevated concentrations of glutamate stimulate the entry of high
levels of calcium into cells or neurons, which is mediated by N‐methyl‐d‐aspartate
(NMDA) receptors that also contribute to cell death. NMDA receptors can be directly
inhibited by NMDA antagonists or indirectly modulated by sigma-1 receptor agonist
[33,36]. Sigma-1 receptor agonists have proven their neuroprotection efficacy by the
inhibition of the glutamate-induced morphological changes and suppression of lactate
dehydrogenase (LDH), which increases tissue damage [37]. Dextromethorphan (DXM) is
a non-competitive NMDA receptor antagonist, sigma1receptor agonist, and calcium
7

channel blocker, thus, it has proven its protective effects on cells and neurons in different
disease models [35,38]. NADPH oxidase activity that is stimulated by voltage-gated
proton channels in different cells such as microglia has a potential role in posing oxidative
stress on cells. DXM has been also reported to inhibit the proton currents which eventually
suppress NADPH oxidase activity and oxidative stress [39].

1.6 Role of Dextromethorphan as a promising anti-oxidant and anti-inflammatory
Dextromethorphan (3-methoxy-N-methylmorphinan) (DXM) has been known for its
antitussive effects as a non-opioid cough suppressant through its N‐methyl‐d‐aspartate
(NMDA) receptor blocking effects in the central nervous system (CNS) [40]. DXM is a
better alternative to opioids due to its less habituating effects and its safety profile in the
gastrointestinal system. After the rapid absorption of DXM from the gastrointestinal tract,
it enters the bloodstream and it can cross the blood-brain barrier (BBB), where it can
exhibit its effects [41]. Due to DXM’s ability to cross the (BBB), and its high safety profile,
researchers have been urged to expand its role beyond being an anti-cough medication,
and explore its pharmacology in the treatment of different neuronal and vascular diseases
that

driven

by

neurotoxicities,

ischemia,

cytotoxicities,

and

inflammation.

Dextromethorphan (DXM) has found many implications in different disease models that
involve inflammation and showed significant potential as an antioxidant and antiinflammatory agent. Liu et al. investigated the role of DXM in mitigating the inflammatory
process in an atherosclerotic model, after having evidence that the drug has a role of
protection against oxidative stress by the inhibition of microglial nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase that induces the superoxide (SOD) release,
8

which is a potential oxidant in cells. The drug inhibited the production of cytokines and
superoxide by reducing macrophages; thus, decreased the formation of atherosclerosis
in mice. In the previous study, a macrophage-cell culture model has been used to show
that the treatment of cells by DXM suppressed the following inflammatory genes, tumor
necrosis factor-α (TNF- α), monocyte chemoattractant protein-1 (MCP-1), interleukin-6
(IL-6), interleukin-10 (IL-10), and superoxide (SOD). Their animal models demonstrated
that the 10-week treatment of DXM (10–40 mg/kg/day) in apoE-deficient mice resulted in
the suppression of SOD production in leukocytes and the aorta and the subsequent
reduction of atherosclerosis formation [42]. Zhang et al. explored the role of DXM as a
potential neuroprotective agent in a Parkinson’s disease model, where oxidative stress
and brain inflammation have a significant role in the degeneration of the dopaminergic
neurons that is the underlying cause of the disease. In their in vitro model, DXM was
found to protect the mesencephalic neuron-glia cells against the endotoxins that induce
dopaminergic neurodegeneration. They also found a profound decrease of both
extracellular (SOD) free radicals and intracellular reactive oxygen species (ROS). They
also investigated the underlying mechanism of DXM neuroprotection in Parkinson’s
disease mice model (C57BL/6J) through the daily subcutaneous injections of DXM (10
mg/kg) to two different groups: a wild-type group and an NADPH oxidase-deficient mice
group, where they found significant preservation of dopaminergic neurons wild-type group
and no effect in the NADPH oxidase-deficient mice group. The previous finding indicates
that the inhibition of NADPH oxidase by DXM has a crucial role in the demonstrated
neuroprotective effect of DXM [43]. Due to several findings, the DXM can protect the
dopaminergic neuronal cells from inflammatory-induced degeneration, a study was
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conducted to investigate the potential role of DXM in preserving the inflammatorymediated endothelial dysfunction in heavy smokers. The drug was given to forty smoking
healthy volunteers for 6 months, then an evaluation of their endothelial function was
performed by measuring the brachial artery diameter changes in flow-mediated dilatation
(FMD) in addition to the inflammatory and oxidative stress markers. The results showed
a total improvement of the FMD by 32% in the DXM-treated group vs. the control group.
The molecular analysis showed a reduction in the following inflammatory markers: Creactive protein (hs-CRP), phospholipase (A 2), matrix metalloproteinase-3, interleukin 6
(IL-6), and tumor necrosis factor-alpha receptor II (TNF-alpha RII). Furthermore, there
was a noticed increase in the plasma glutathione peroxidase, which is an important antioxidant. The previous findings proved the role of DXM in improving endothelial function
and protecting providing vascular protection against oxidative stress and inflammation in
smokers [44].

Pu et al. have investigated the underlying mechanism of the DXM

neuroprotective effect in the traumatic brain injury animal model. After subjecting the rats
to the cortical impact injury, a group of animals was given intraperitoneal DXM (30 mg/kg)
injections after the injury; and a profound reduction of the brain edema and neurological
injuries were observed in addition to the improvement of the neuronal survival. A
decrease in the inflammatory protein expression such as TNF-α, IL-1β, and IL-6 was also
detected with an upregulation of glutamate/aspartate transporter and glutamate
transporter-1 in the brain cortex. The upregulation of glutamate transporters has an antiexcitatory effect on cells due to their active role in the clearance of the accumulated
extracellular glutamate that results from the overstimulation of glutamine receptors that
induce the production of excitotoxic ROS and Nitrogen species [33]. In their study to test
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the anti-oxidant role of DXM in a Vascular Dementia mouse model, Xu et al. have shown
that the activation of the Nrf2-HO-1 pathway and the increase of SOD expression were
the underlying mechanisms of DXM protection against oxidative stress [45]. Another
proposed mechanism of DXM protection as a low-affinity NMDAR antagonist against
excitotoxic brain damages was reported by Keller et al., who demonstrated the
association of the cell death reduction by death with the decrease of Fluoro‐Jade B
stained microglia and caspase‐3 pathway inhibition [46]. Since several neurological
disorders are associated with pseudobulbar affect (PBA) that is an emotional disorder
characterized by unstable emotional states, some studies have demonstrated the
effective role of DXM in reducing the symptoms in patients of this disease due to its safety
profile and its ability to cross the (BBB). The results were thought to be attributed to DXM
non-competitive NMDA receptor antagonism, and a sigma1receptor agonism. Besides,
these studies showed that the co-administration of small doses of Quinidine with DXM
was beneficial in increasing DXM bioavailability in the bloodstream as Quinidine inhibits
the fast metabolism of DXM [47-49].

1.7 Role of N-Methyl-D-aspartate (NMDA) Receptor in Retinal Excitotoxicity
Glutamate and aspartate are major amino acids in retinal neurons that can
overstimulate glutamate receptors through NMDA receptors, and this overstimulation has
detrimental effects on retinal and photoreceptor cells due to high oxidative stress and the
consecutive inflammatory response [34], [50], [51]. There have been numerous studies
evaluating the role of NMDA receptor antagonists involving DXM in mitigating cellular
inflammatory responses and enhancing cell survival in ocular diseases including the
11

retina. Michael et al. have investigated the role of DXM in blocking NMDA-mediated
glutamate toxicity in neonatal retinal development in rabbits, and they found significant
retinal survival after treatment with DXM [34]. Yoon et al. have shown the post-ischemic
recovery of retinal b-wave in the intravenously injected pre-treated rabbits with DXM
compared to the retinal ischemic group [52]. Dextromethorphan could prove its antioxidant and anti-inflammatory effects as an NMDA receptor antagonist in previous
oxidative stress and inflammatory models as previously described. Accordingly, our study
aims to evaluate the role of Dextromethorphan, N-Methyl-D-aspartate (NMDA) receptor
antagonist in protecting retinal pigment epithelial cells (RPE) from paraquat and
hydroquinone induced oxidative stress and consecutive inflammatory stress. This can be
investigated through cell viability and apoptosis assays, and the underlying molecular
biology mechanisms of protection can be explained by conducting the RNA analysis.
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Chapter 2
Materials & Methods

2.1 Materials
The materials used in each experiment are listed below each subsection.

2.1.1 General Reagents

Dextromethorphan hydrobromide (D9684), Paraquat dichloride hydrate (36541),
Hydroquinone (H9003), and Dimethyl Sulfoxide (DMSO) (D2650) were ordered from
Sigma-Aldrich. MTT (3-(4,5 Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) dye
(M6494) was purchased from Thermo Fisher Scientific (M6494).

2.1.2 Cell Culture
Human retinal pigment epithelial (ARPE-19) cells were obtained from ATCC
(CRL-2302, Lot Number 7022669; Manassas, VA), and cultured in T-75 flasks, 96-well
plates, or 6-well plates. Cells were incubated in Sigma’s Dulbecco’s Modified Eagle’s
Medium/Nutrient Mixture F-12 Ham (D6421), and the media was supplemented with
0.365 g/L of L-Glutamine (G8540), 5% Fetal Bovine Serum (G6279), and 1% PenicillinStreptomycin (P0781) were purchased from Sigma (St. Louis, MO). PBS - Phosphate13

Buffered Saline and Trypsin- EDTA 25% were ordered from Thermo fisher scientific.
Incubator conditions were kept at 37º C with a 5% CO2 level.

2.1.3 Flow Cytometry
Samples staining preparation reagents were purchased from Biolegend, including
BioLegend Cell Staining Buffer (Cat. No. 420201), Annexin V Binding Buffer (Cat. No.
422201) APC Annexin V (Cat. No. 640920), DAPI solution (Cat. No. 62248). The flow
cytometry results were recorded on a Becton Dickinson LSRII Flow Cytometer (San Jose,
CA), Data was recorded and analyzed with FacsDiva6.1.3 software.

2.1.4 RNA Analysis Materials
Mini Kit (74104) was purchased from Qiagen. Ultrasonic Cell Disruptor 20KHZ
500W Homogenizer ¼ was used for sample preparation. Thermo Scientific Legend
micro 21 Centrifuge was used in the RNA purification process. cDNA was synthesized
using iTaq Universal SYBR® Green Supermix (Catalog no. 1725120) and amplified
using T100™ Thermal Cycler (Cat. No. 1861096).

2.2 Optimization of Cells Seeding Density for MTT Cell Viability Assays

ARPE-19 cells with densities ranging from 2,000 to 20,000 cells were seeded in a
96 well-plate in 6 replicates and incubated for 48 hours at 37º C. At the end of the
incubation period, 100 µL of the MTT reagent dissolved in PBS solution and incomplete
media with 1% Penicillin/ Streptomycin at a concentration of 0.5 mg/ml was added and
14

incubated with cells for 4 hours at 37º C. At the end of the 4-hour incubation period, the
MTT solution was removed and formazan crystals were dissolved with 100 µL of DMSO.
100 µL of DMSO was also added to 6 empty wells to serve as a blank during the
absorbance measurements to subtract any background absorbances. The plate was then
measured for absorbance (OD 540 nm) using Biotek Synergy Neo2 Hybrid Multi-Mode
plate reader. A graph representing the seeding density versus absorbance was obtained
and the highest seeding density producing an absorbance in the cells’ linear growth phase
was used for the following cell viability assays.

2.3 Anti-oxidant effect of Dextromethorphan
MTT Assays were conducted to optimize the Dextromethorphan treatment doses,
and the paraquat (PQ) and hydroquinone (HQ) different doses that induce oxidative
stress. The anti-oxidant effects of DXM in different doses were evaluated in three
different treatment approaches against different doses each of the two oxidants
(Paraquat and Hydroquinone).

2.3.1 Optimization of the cytotoxic effect doses of Paraquat & Optimization of
Dextromethorphan Optimum Treatment Doses

An MTT assay was performed to determine the optimum doses of Paraquat that
should be used to induce oxidative stress in cells and produce cell death to test the antioxidant effects of dextromethorphan in the subsequent experiments. A 96-well plate was
seeded with 6,000 cells per well and incubated at 37º C for 48 hours. At the end of the
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incubation period, the media was removed and a 100 µL of Paraquat diluted in incomplete
media at concentrations of 200 µM, 400 µM, 600 µM, 800 µM, and 1000 µM was added
to cells in triplicates. In the remaining wells, cells were treated with triplicates of 7 different
concentrations of Dextromethorphan hydrobromide (1 nM, 100 nM, 1µM. 10 µM, 20 µM,
30 µM, and 50 µM) diluted in incomplete media. A 6-replicate negative control group of
cells in media was left untreated. The plate was incubated at 37 ºC for 24 hours, then
treatments were removed, and 100 µL of MTT dye (0.5 mg/ ml) was added to all wells,
and then the plate was incubated at 37 ºC for 4 hours. After incubation, MTT was removed
and replaced with DMSO that was added to all wells including the negative control group
and 6 empty wells to serve as a blank. The absorbance (OD 540 nm) was measured
using Biotek plate reader. The cell viability of the treated samples was represented as a
percentage of the control (untreated samples). A line graph of the cell viability versus the
concentration of Paraquat and Dextromethorphan was produced for analysis. The two
effective doses of Paraquat reagent that produced cell death in minimal concentrations
were used to induce oxidative stress in ARPE-19 cells in all subsequent experiments.
From the seven concentrations of Dextromethorphan, four effective concentrations (10,
20, 30, and 50 µM) were chosen as the treatment doses in the following MTT Assays,
then DX 10 µM was selected as the minimal effective dose and DX 30 µM was selected
as the maximally effective dose.

2.3.2 Optimization of the cytotoxic doses of Hydroquinone
An MTT assay was performed to determine the optimum doses of Hydroquinone
that should be used to induce oxidative stress in cells and produce cell death to test the
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anti-oxidant effects of dextromethorphan in the subsequent experiments. A 96-well plate
was seeded with 6,000 cells per well and incubated at 37º C for 48 hours. At the end of
the incubation period, the media was removed and a 100 µL of Hydroquinone that is
diluted in incomplete media at concentrations of 100µM, 200 µM, 500 µM was added to
cells in 6-replicate groups. A 6-replicate negative control group of cells in media was left
untreated. The plate was incubated at 37 ºC for 24 hours, then treatments were removed,
and 100 µL of MTT dye (0.5 mg/ ml) was added to all wells, and then the plate was
incubated at 37 ºC for 4 hours. After incubation, MTT was removed and replaced with
DMSO that was added to all wells including the negative control group and 6 empty wells
to serve as a blank. The absorbance (OD 540 nm) was measured using Biotek plate
reader. The cell viability of the treated samples was represented as a percentage of the
control (untreated samples). A line graph of the cell viability versus the concentration of
Hydroquinone was produced for analysis. Two effective doses of Hydroquinone reagent
that produced cell death as a minimal and a maximµM lethal concentration (200 and 400
µM) were used to induce oxidative stress in ARPE-19 cells in the subsequent
experiments.

2.4 Investigating the Protective Effect of Dextromethorphan for ARPE-19 Cells
To investigate the protective effect of Dextromethorphan for ARPE-19 Cells
against Paraquat and Hydroquinone induced oxidative stress through MTT cell viability
assays. Three approaches of the evaluation were used, the first approach involved the
treatment of cells with a combination of the oxidative stress inducers (Paraquat 400 µM
and 600 µM/ Hydroquinone 200 µM and 400 µM) with DX (10 µM and 30 µM), the second
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approach involved the pre-treatment of cells with the oxidative stress inducers (Paraquat
400 µM and 600 µM/ Hydroquinone 200 µM and 400 µM), then DX 10 µM and 30 µM,
and the third approach involved the post-treatment of cells with the oxidative stress
inducers (Paraquat 400 µM and 600 µM/ Hydroquinone 200 µM and 400 µM), then DX
10 µM and 30 µM.

2.4.1 Measuring the Combined Effect of Dextromethorphan & Paraquat on ARPE19 Cells

An MTT assay was performed to investigate the protective effect of
Dextromethorphan for ARPE-19 Cells against Paraquat and Hydroquinone-induced
oxidative stress. A 96-well plate was seeded with 6,000 cells per well in a volume of 100
µL/well in DMEM/F12 complete media and incubated at 37º C for 48 hours. At the end of
the incubation period when cells reached approximately 80% confluence, the media was
removed and 100 µL of each treatment condition that is diluted in incomplete media was
added to cells. Five treatment conditions of the 6-replica/ group were maintained, and the
6-replicate negative control group of cells in incomplete media was left untreated. The
treatment conditions included, two positive control groups that were treated with
(Paraquat 400 µM and 600 µM), two treatment control groups that were treated with DX10
and 30 µM, and the last four groups were treated respectively as follows, a combination
of Paraquat 400 µM with DX10 µM, a combination of Paraquat 400 µM with DX30 µM, a
combination of Paraquat 600 µM with DX10 µM, and a combination of Paraquat 600 µM
with DX30 µM. The plate was incubated at 37 ºC for 24 hours, then treatments were
removed, and 100 µL of MTT dye (0.5 mg/ ml) was added to all wells, and then the plate
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was incubated at 37 ºC for 4 hours. After incubation, MTT was removed and replaced
with DMSO that was added to all wells including the negative control group and 6 empty
wells to serve as a blank. The absorbance (OD 540 nm) was measured using Biotek plate
reader. The cell viability of the treated samples was represented as a percentage of the
control (untreated samples). A line graph of the cell viability versus the concentration of
each treatment was produced for analysis.

To evaluate the behavior of cells to the combined effect of Hydroquinone and
Dextromethorphan, the same experimental design and conditions were used, using
Hydroquinone 200 and 400 µM, and DX 10 and 30 µM. The cell viability of the treated
samples was represented as a percentage of the control (untreated samples). A line
graph of the cell viability versus the concentration of each treatment was produced for
analysis.

2.4.2 Dextromethorphan Pre-treatment of Cells before oxidative stress induction

An MTT assay was performed to investigate the protective effect of
Dextromethorphan for ARPE-19 Cells against Paraquat and Hydroquinone-induced
oxidative stress. A 96-well plate was seeded with 6,000 cells per well in a volume of 100
µL/well in DMEM/F12 complete media and incubated at 37º C for 48 hours. At the end of
the incubation period when cells reached approximately 80% confluence, the media was
removed and 100 µL of each treatment condition that is diluted in incomplete media was
added to cells. Five treatment conditions of the 6-replica/ group were maintained, and the
6-replicate negative control group of cells in incomplete media was left untreated. The
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treatment conditions included, two positive control groups that were treated with
(Paraquat 400 µM and 600 µM), two treatment control groups that were treated with DX10
and 30 µM, and two extra groups of cells were pre-treated with DX 10 µM, and two others
were pre-treated with DX 30 µM. After a 24-hour incubation period at 37 ºC, the four extra
groups of DX 10 and 30 µM were post-treated with Paraquat 400 and 600 µM. The plate
was incubated at 37 ºC for another 24 hours, then treatments were removed, and 100 µL
of MTT dye (0.5 mg/ ml) was added to all wells, and then the plate was incubated at 37
ºC for 4 hours. After incubation, MTT was removed and replaced with DMSO that was
added to all wells including the negative control group and 6 empty wells to serve as a
blank. The absorbance (OD 540 nm) was measured using a Biotek plate reader. The cell
viability of the treated samples was represented as a percentage of the control (untreated
samples). A line graph of the cell viability versus the concentration of each treatment was
produced for analysis.

To evaluate the behavior of cells to the effect of DX10 and 30 µM treatment before
the induction of oxidative stress damage by Hydroquinone 200 and 400 µM. The same
previous experimental design and conditions were used; however, the incubation period
after the cells were treated with Hydroquinone (HQ 200 and 400 µM) was shortened to 46 hours before the MTT treatment. The cell viability of the treated samples was
represented as a percentage of the control (untreated samples). A line graph of the cell
viability versus the concentration of each treatment was produced for analysis.
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2.4.3 Dextromethorphan Post-treatment of ARPE-19 Cells After Induction of
Oxidative Stress Damage

An MTT assay was performed to investigate the protective effect of
Dextromethorphan for ARPE-19 Cells after the induction of oxidative stress damage by
Paraquat and Hydroquinone. A 96-well plate was seeded with 6,000 cells per well in a
volume of 100 µL/well in DMEM/F12 complete media and incubated at 37º C for 48 hours.
At the end of the incubation period when cells reached approximately 80% confluence,
the media was removed and 100 µL of each treatment condition that is diluted in
incomplete media was added to cells. Five treatment conditions of the 6-replica/ group
were maintained, and the 6-replicate negative control group of cells in incomplete media
was left untreated. The treatment conditions included, two positive control groups that
were treated with (Paraquat 400 µM and 600 µM), two treatment control groups that were
treated with DX10 and 30 µM, and two extra groups of cells were pre-treated with
Paraquat 400 µM, and two others were pre-treated with Paraquat 600 µM. After a 24hour incubation period at 37 ºC, the four extra groups of Paraquat 400 and 600 µM were
post-treated with DX 10 and 30 µM. The plate was incubated at 37 ºC for another 24
hours, then treatments were removed, and 100 µL of MTT dye (0.5 mg/ ml) was added to
all wells, and then the plate was incubated at 37 ºC for 4 hours. After incubation, MTT
was removed and replaced with DMSO that was added to all wells including the negative
control group and 6 empty wells to serve as a blank. The absorbance (OD 540 nm) was
measured using a Biotek plate reader. The cell viability of the treated samples was
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represented as a percentage of the control (untreated samples). A line graph of the cell
viability versus the concentration of each treatment was produced for analysis.

To evaluate the behavior of cells to the effect of DX10 and 30 µM treatment after
the induction of oxidative stress damage by Hydroquinone 200 and 400 µM. The same
previous experimental design and conditions were used; however, the incubation period
of the cell with the Hydroquinone (HQ 200 and 400 µM) was shortened to 4-6 hours before
the addition of DX10 and 30 µM. The cell viability of the treated samples was represented
as a percentage of the control (untreated samples). A line graph of the cell viability versus
the concentration of each treatment was produced for analysis.

2.5 Apoptosis Evaluation by the Flow Cytometry
ARPE-19 cells with a cell seeding density of 300,000 cells/ well were seeded in
three 6- well plates in complete media of DMEM F12 and incubated for 48 hours at 37 ºC.
To evaluate the apoptotic behavior of cells under different conditions, six groups were
arranged in triplicates the following order: negative control group (cells without any
treatment), positive control (Hydroquinone 400 µM) to induce oxidative stress,
Dextromethorphan (Dx 10 µM) group, Dextromethorphan (Dx 30 µM), and the last two
groups of cells were pre-treated with Dextromethorphan (Dx 10 µM) and (Dx 30 µM), and
after 4-6 hours of incubation at 37 ºC, both groups were treated with Hydroquinone 400
µM to induce oxidative stress. After incubation cells were imaged using the Keyence
Microscope and cells were detached using Trypsin- EDTA 25%, and centrifuged at 800
revolutions per minute (RPM) for 6 minutes. The supernatant was discarded, and pellets
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were re-suspended in a (1ml) of cold BioLegend Cell Staining Buffer (Cat. No. 420201).
Cell suspensions were centrifuged at 800 RPM for 6 minutes, and the cell pellets were
re-suspended in (100µl) of Annexin V Binding Buffer (Cat. No. 422201) at a concentration
of 1x106 cells/ml. The 100µl cell suspensions were transferred to 5 ml flow cytometry
falcon tubes, and 5 µl of APC Annexin V dye (Cat. No. 640920) were added to each tube,
then 2 µl of 0.1 ug/ml DAPI solution (Cat. No. 62248) were added to each tube. The tubes
were gently vortexed and cells were incubated for 15 min at room temperature (25°C), in
the dark. After incubation, 400 µl of Annexin V Binding Buffer (Cat. No. 422201) was
added to each tube. The samples were then analyzed by flow cytometry. The results were
recorded on a Becton Dickinson LSRII Flow Cytometer (San Jose, CA), using 405 nm
laser to excite DAPI that was measured at 450/50 nm wavelength, and 633 nm laser
excitation for APC that was measured at 660/20 nm. The data was recorded and
analyzed with FacsDiva6.1.3 software.

2.6 Testing for Anti-Oxidant and Anti- inflammatory Gene Expression in Response
to Dextromethorphan Treatment

ARPE-19 cells were seeded in three 6-well plates at a density of 300,000 cells per
well in DMEM/F12 complete media and incubated for 48 hours at 37º C to reach 80%
confluence. After incubation, the media was removed, and a triplicate of each group was
treated as follows: a negative control group that was treated with DMEM/F12 incomplete
media, a positive control group that was treated with Paraquat, two groups were treated
with DX10 and 30 µM, and two groups were separately treated with combinations of
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DX10+Paraquat and DX30+Paraquat. After 24-hour incubation at 37º C, then cells were
ready for RNA isolation and purification using the RNeasy Mini Kit.

2.6.1 RNA Isolation and Quantification
One ml of PBS (1X) was added to each well for washing. Then, to purify RNA from
cell lines 10 μl β-mercaptoethanol (β-ME) were added to every 1 ml Buffer RLT, 350 μl of
the mixture were added to each well to scrape cells off. One volume of 70% ethanol (350
μl) was added to each good lysate and mixed well by pipetting. Then, the 700 μl of each
sample, including any precipitate were transferred to RNeasy Mini spin columns that are
placed in 2 ml collection tubes (supplied in the kit), samples were homogenized for 10
seconds each using an ultra-sonicator to be centrifuged for 15 s at ≥ 8000 x g. The flowthrough was discarded, 700 μl Buffer RW1 was added to each RNeasy spin column,
centrifuged for 15 s at ≥ 8000 x g and the flow-through was discarded. Then, a 500 μl of
Buffer RPE working solution (1 volume of Buffer RPE: 4 volumes of 90-100% ethanol)
were added to each RNeasy spin column, centrifuge for 15 s at ≥ 8000 x g, and the flowthrough was discarded. A 500 μl Buffer RPE was added to each RNeasy spin column,
samples were centrifuged for 15 s at ≥ 8000 x g, the flow-through was discarded and this
step was repeated with a centrifugation time of two minutes. The RNeasy spin columns
were placed in a new 1.5 ml collection tube that was also supplied with the kit, 20 μl
RNase-free water was added directly to the spin column membranes, and samples were
centrifuged for 1 min at ≥ 8000 x g to elute the RNA. The flow-through was collected from
each collection tube and added to each corresponding spin column again to get a more
concentrated RNA. To quantify the RNA, Thermo Scientific™ NanoDrop™ OneC
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Microvolume UV-Vis Spectrophotometer was used with 1 μl volume used for each sample
measurement.

2.6.2 cDNA Synthesis
The cDNA was synthesized using iScript™ Reverse Transcription Supermix for
RT-qPCR, and all the reaction set-up steps were assembled on ice. PCR tubes were set
up for each sample in triplicates, 4 μl of iScript RT Supermix were added to each tube,
and RNA template and NF water were added to each tube based on the RNA
concentration calculations, whereas the total volume of each sample was 20 μl. The
samples were mixed thoroughly by pipetting up and down several times. The complete
reaction mixtures were incubated in BioRad thermal cycler, using the following protocol:
priming for 5 min at 25°C, reverse transcription for 20 min at 46 °C, and RT inactivation
for 1 min at 95 °C.

2.6.3 cDNA Amplification and Testing
The iTaq Universal SYBR® Green Supermix was used for the Polymerase Chain
Reaction (PCR) amplification. The Thaw iTaq Supermix was thawed and other frozen
reaction components to room temperature, mixed thoroughly, centrifuged shortly to
collect solutions at the bottom of tubes, then they were kept on ice protected from light.
Enough reaction master mix was prepared for all qPCR reactions by adding all required
components, except the DNA template, according to the following: 3 μl of Nuclease free
water, 0.5 μl of each forward and reverse primers of Occludin, and 5 μl of iTaq Supermix.
The reaction master mix was mixed properly to ensure homogeneity and dispense equal
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aliquots into each qPCR tube or the wells of a qPCR plate. Then, 1 μl of the cDNA of
each sample was added to the corresponding PCR tubes or wells containing the reaction
master mix. Tubes or wells were sealed using caps or a transparent film, and vortexed
for 30 sec or more to ensure thorough mixing of the reaction components. Then, they
were spun down to remove any air bubbles and to ensure that the reaction mixtures are
in the vessels’ bottom. The thermal cycling protocol was programmed on the real-time
PCR instrument according to the following steps: polymerase activation and DNA
Denaturation at 95 °C 20–30 secs, cDNA amplification (Denaturation at 95 °C, 2–5 secs,
Annealing/Extension and Plate Read at 60 °C, 15-20 sec) for 35-40 cycles, and the Melt
Curve Analysis was done at 65–95 °C 0.5°C increments at 2–5 sec/step. PCR tubes or
plates were loaded into the real-time PCR instrument and the PCR machine was started.

2.6.4 Gel Electrophoresis and Imaging
The gel electrophoresis was done using the Biorad Powerpack gel electrophoresis
instrument, and the process involved the following steps: pouring the gel, mixing (10μl) of
each sample with a (2μl) of a DNA staining dye (Tritack), loading the gel, running the gel.
A 1.5% agarose gel in 1X TAE buffer with 5 μl Ethidium Bromide gel-staining dye was
prepared and poured into the gel electrophoresis mold with combs and was allowed to
cool down. After cooling down and getting solidified, the combs were removed and 1xTAE
buffer was added to cover the gel and wells. For sample preparation, 2 μl of the DNA
loading dye were added to each sample to allow for visualization of samples upon gel
imaging, vortexed gently, and centrifuged for thorough mixing and air bubble removal.
Samples were then loaded to the gel, and the electric field was set at 130 Volts for 40
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minutes. The agarose gel was allowed to run until the dye has migrated about halfway
from the wells to the end of the gel. Gels were imaged using Biorad Gel Doc and the
bands are shown in the results section.

2.6.4.1 Primers Reconstitution and Quality Testing

The newly purchased primers that were shipped in a lyophilized state were
reconstituted in TE (10 mM Tris, 0.1 mM EDTA, pH 8.0) buffer as follows; all tubes were
spun down, and to determine the amount of TE buffer to add to the lyophilized primer, the
number of (n) mols of primer in the tube was be multiplied by 10 and the resultant is equal
to the volume of the TE buffer to be added to make a 100 μM primer’s stock. Primers
were then gently vortexed and diluted in a sterile microcentrifuge tube as 1:10 with sterile
molecular grade water. All primers were Labelled and stored in -20 for future use. To test
for the quality of each primer that will be used in all of the further sets of experiments, the
cDNA of samples was used with all primers in PCR reactions and the imaged gels with
the revealed bands are shown in the results section.

2.6.4.2 Testing for ARPE-19 Cell-specific genes

The cDNA samples were tested for the following cell specificity genes: β- actin,
BEST-1, GAPDH, ITGB-5, MERTK-1, and OCCLN by setting three PCR plates that were
sufficient to test each of these genes twice in all of the cDNA samples that were in
triplicates. All plates included six non-template controls (NTC), which are wells that were
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filled with PCR master mix reactions without cDNA samples. All the gels were imaged,
and the bands revealed are shown in the results section.

2.6.4.3 Testing for ARPE-19 Anti-oxidant genes

The cDNA samples were tested for the following protective anti-oxidant genes:
NQO-1, GSTM-1, HO-1, NRF-2, GCLM, 18s-rRNA, MT-1, and NOTCH-1 by setting six
PCR plates that were sufficient to test each of these genes twice in all of the cDNA
samples that were in triplicates. All plates included six non-template controls (NTC), which
are wells that were filled with PCR master mix reactions without cDNA samples. All the
gels were imaged and the bands revealed are shown in the results section.

2.6.4.4 Testing for Anti-inflammatory genes

The cDNA samples were tested for the following protective anti-oxidant genes: IL1 β, IL-6, IL-17, IL-18, GAPDH, MCP-1, TNF- α, IFN- β, VEGF- α, CCL-2, and β-actin by
setting six PCR plates that were sufficient to test each of these genes twice in all of the
cDNA samples that were in triplicates. All plates included six non-template controls
(NTC), which are wells that were filled with PCR master mix reactions without cDNA
samples. All the gels were imaged and the bands revealed are shown in the results
section.
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Chapter 3
Results

2Figure

3.1 MTT Cell Viability Assay for Cell Seeding Density Optimization. Cell

titration is from 5000 to 25000 cell per well.

Figure 3.1 shows that seeding plates with a density of 6000 cells per well is the
optimum number for maintaining the sensitivity of the MTT assay. The absorbance
increases with the increase of cell seeding density and reaches a plateau when the cell
seeding density was more than 6000 cells per well.
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3.2 Optimization of the cytotoxic effect doses of Paraquat

3Figure

3.2 MTT Assay Results for ARPE-19 Cell Viability After Paraquat

Treatment (Trial 1).ARPE-19 cell viability after 24 h treatment of of 200-1000 µM of
Paraquat.

Figure 3.2 shows the results of ARPE-19 cell viability after treatment of 200, 400,
600, 800 and 1000 µM of the oxidative reagent (Paraquat). Increasing the concentration
of paraquat produced a gradual decline in cell viability. The same results were confirmed
in Figure 3.3.
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4Figure

3.3 MTT Assay Results for ARPE-19 Cell Viability After Paraquat

Treatment (Trial 2). ARPE-19 cell viability after 24 h treatment of 600 and 800µM of
Paraquat.

3.3 Optimization of Dextromethorphan Optimum Treatment Doses

5Figure

3.4 MTT Assay Results of Concomitant Effect of DXM and PQ On ARPE-

19 Cells.The concomitant effect of DXM (10, 20,30 & 50 µM) + PQ 600µM on ARPE-19
cells.
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Figure 3.4 shows that the concomitant treatment of DXM (10, 20,30 & 50 µM) with
Paraquat 600µM on ARPE-19 cells could lead to cell survival by more than 50%.

3.4 Optimization of the cytotoxic doses of Hydroquinone
Figure 3.5 displays the morphological differences between three conditions, (A)
ARPE-19 healthy cells, where the cell barrier integrity is maintained all over the imaging
fields, while in (B), ARPE-19 cells were exposed to oxidative stress by Hydroquinone
200µM, which resulted in the disruption of the cell membrane integrity. In (C), ARPE-19
cells that were pre-treated with DXM 30 µM before oxidative stress induction by
Hydroquinone 200 µM maintained their membrane’s integrity, which demonstrates the
protective effect of DXM for cells.

6Figure

3.5 ARPE-19 cell morphology changes. (A) Healthy Control Cells Vs. (B)

Hydroquinone 200µM Stressed Cells and (c) Hydroquinone 200µM+ DXM 30µM Treated
Cells).
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7Figure

3.6 Classic MTT Assay Results of ARPE-19 Cell Viability After treatment

with Hyroquinone.Cell Viability was measured after 48 h treatment of Hyroquinone (HQ)
200 and 500 µM.

Figure 3.6 shows the gradual decrease of cell viability percent upon the increase
of Hydroquinone doses (200-500µM). Hydroquinone doses of 200 µM and 400 µM were
selected as the oxidative stress-inducing doses.
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8Figure

3.7 Classic MTT Assay to Evaluate the Effect of Different Doses of DXM

Pre-Treatment On ARPE-19 Cells Before Oxidative Stress Induction by Paraquat. Effect
of DXM (10,20,30 &50µM) pre-treatment on ARPE-19 cells before oxidative stress
induction by PQ 600µM.

Figure 3.7 shows that the pre-treatment of ARPE-19 cells with DXM (10,20,30
&50µM) before inducing cell death by paraquat 600µM could result in around 30-40 %
increase in cell survival as compared to the paraquat 600 µM treated group. The posttreatment of ARPE-19 cells with different doses of DX (10,20,30 &50µM) after inducing
cell death by paraquat 600µM could also lead to cell survival by around 15 - 25% as
compared to the positive controls in Figure 3.8.
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9Figure

3.8 MTT Assay Results to Evaluate the Post-Treatment Effect of DXM After

Oxidative Stress Induction by Paraquat (PQ) On ARPE-19 Cells. Different doses of DXM
(1 nM, 100 nM, 1 uM, 10uM and 30 uM) were used after PQ 600µM treatment.
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3.5 Investigating the Protective Effect of Dextromethorphan for ARPE-19 Cells
against Hydroquinone

10Figure

3.9 MTT Assay Results for Combined Effect of DXM and Hydroquinone

(HQ) On ARPE-19 Cells.Six replicas of each group were included with different doses of
(DXM 10 &30 µM + Hydroquinone (HQ) 200µM).

Figure 3.9 shows the effect of the combined treatment of ARPE-19 cells with DXM
10 &30 µM + Hydroquinone (HQ) 200µM shows a higher cell survival as compared to the
positive control; however, DXM 30µM could provide a more significant percentage of cell
viability. While figure 3.10 demonstrates the pre-treatment effect of DXM 10 &30 µM (1618) hours before induction of Oxidative Stress by Hydroquinone (HQ) 200µM & 400 µM
on ARPE-19 cells was shown to protect cells; and the 10µM dose of DXM could protect
against the lower dose of HQ (200µM), while DXM 30µM showed better protection against
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the high HQ dose (400µM). In (3.11); nevertheless, there was no protection shown in the
condition of the post-treatment of ARPE-19 cells with (DXM 10 &30 µM (4-6) hours after
the induction of Oxidative Stress by Hydroquinone (HQ) 200µM & 400 µM (Left-sided
group).

11Figure

3.10 MTT Assay Results for the Pre-Treatment Effect of DXM Against

Hydroquinone (HQ) On ARPE-19 Cells.Pre-treatment effect of DXM 10 &30 µM (16-18)
hours before induction of Oxidative Stress by Hydroquinone (HQ) 200µM & 400 µM on
ARPE-19 cells.
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12Figure

3.11 Classic MTT. Post-Treatment Effect of DXM Against Hydroquinone.

(HQ) On ARPE-19
.Figure 3.11 shows the cell viability assay’s results of the post-treatment effect of DXM
10 &30 µM (4-6) hours after induction of Oxidative Stress by Hydroquinone (HQ) 200µM
& 400 µM on ARPE-19 cells (Left-sided group) Vs. Pre-treatment effect of DXM 10 &30
µM (16-18) hours before induction of Oxidative Stress by Hydroquinone (HQ) 200µM &
400 µM on ARPE-19 cells (Left-sided group) Vs. Pre-treatment effect of DXM 10 &30 µM
(16-18) hours before induction of Oxidative Stress by Hydroquinone (HQ) 200µM & 400
µM on ARPE-19 cells.

3.6 Apoptosis Evaluation by the Flow Cytometry
The more Annexin V bound cells in the right quadrants, the higher the number of
early and late apoptotic cells. The illustration in Figures 3.12, 3.13 & 3.14 shows the flow
Cytometry results from a triplicate of samples: Control [C] Vs. Treatment Groups
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[Hydroquinone 400µM (Q), DXM 10 &30µM (D10&D30), DXM 10 & 30µM pre-treatment
of cells before oxidative stress induction by Hydroquinone (DQ10 & DQ30). As shown,
the healthy control cells (C1, C2 & C3) demonstrated the least apoptotic events, DXM (10
&30µM) were shown to be relatively safe on cells with minimal apoptotic events, and the
groups that were pre-treated with DXM10 and 30µM showed significantly lower apoptotic
events as compared to the Hydroquinone 400µM treated cells. Figure 3.15 demonstrates
that fewer apoptotic events were shown with DXM 10µM.

13Figure

3.12 Flow Cytometry Using Annexin V APC-A to Evaluate ARPE-

19 Cell Apoptosis (First Replica). Control [C] Vs. Treatment Groups [Hydroquinone
400uM (Q), DXM 10 &30uM (D10&D30), DXM 10 & 30uM pre-treatment of cells
before oxidative stress induction by Hydroquinone (DQ10 & DQ30).
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14Figure

3.13 Flow Cytometry Using Annexin V APC-A to Evaluate ARPE-19 Cell

Apoptosis. (Second Replica). Control [C] Vs. Treatment Groups [Hydroquinone 400µM
(Q), DXM 10 &30µM (D10&D30), DXM 10 & 30µM pre-treatment of cells before
oxidative stress induction by Hydroquinone (DQ10 & DQ30).

15Figure

3.14 Flow Cytometry Using Annexin V APC-A to Evaluate ARPE-19 Cell

Apoptosis (Third Replica). Control [C] Vs. Treatment Groups [Hydroquinone 400µM (Q),
DXM 10 &30µM (D10&D30), DXM 10 & 30µM pre-treatment of cells before oxidative
stress induction by Hydroquinone (DQ10 & DQ30).
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16Figure

3.15 Flow Cytometry Using Annexin V APC-A to Evaluate ARPE-19 Cell

Apoptosis Control [C] Vs. Treatment Groups [Hydroquinone 400µM (Q), DXM 10 &30µM
(D10&D30), DXM 10 & 30µM pre-treatment of cells before oxidative stress induction by
Hydroquinone (DQ10 & DQ30).

3.7 Testing for Anti-Oxidant and Anti- inflammatory Gene Expression in Response
to Dextromethorphan Treatment

Primers quality check, cDNA testing and ARPE-19 cell specificity m-RNA
expression genes were vital experiments to be conducted before heading to the
investigation of the molecular mechanisms of DXM protection in cells. After ensuring that
all the primers to be used in experiments are working efficiently as shown in Figure 3.17,
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and all the cDNA of treatments samples in (Figure 3.16) Dextromethorphan (Dex 10 &
Dex 30µM), Paraquat (P600 µM), and Dextromethorphan (Dex 10 & Dex 30µM) +
Paraquat (P600 µM) treated ARPE-19 had the ARPE-19 cell-specific genes (ITGB5, Best1, Occludin, MERTK-1 & GAPDH) as compared to the health ARPE-19 control group as
shown in (Figures 3.18 and 3.19).

3.7.1 cDNA Testing

17Figure

3.16 Testing cDNA Samples against OCCLN. Three replicas of ARPE-19

control group, DXM 10 µM (D10), DXM 30µM (D30), Paraquat 600µM (P),
Paraquat600µM + DXM.
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3.7.2 Primers Testing

18Figure

3.17 Primers Quality Check.Testing inflammatory Primers against cDNA:

(3 replicates) of (ARPE-19 control group [C] Paraquat 600µM [P].

3.7.3 Testing for ARPE-19 Cell-specific genes

19Figure

3.18 Testing for ARPE-19 Cell-Specific Gene Expression. Genes tested:

(ITGB5, Best-1, Occludin, MERTK-1, B-Actin & GAPDH) in Dextromethorphan (DX30µM)
+ Paraquat (P600 µM) treated ARPE-19 cells.
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20Figure

3.19 Impact of DXM on Cell Specific Genes Expression. Testing for

ARPE-19 Cell-specific gene expression (ITGB5, Best-1, Occludin, MERTK-1 & GAPDH)
in Dextromethorphan (Dex 10 & Dex 30µM), Paraquat (P600 µM) and Dextromethorphan
(Dex 10 & Dex 30µM) + Paraquat (P600 µM) treated ARPE-19.

21Figure

3.20 Testing for ARPE-19 Protective Genes Expression (Group1): (MT-

1, NQO-1,18s-rRNA, HO-1) in Dextromethorphan (D30µM) and Dextromethorphan
(D30µM) + Paraquat (P600 µM) treated ARPE-19 cells.
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3.7.4 Testing for ARPE-19 Anti-oxidant (Protective) genes
Figures (3. 20, 3.21 & 3.22) show ARPE-19 protective genes expression (MT-1,
NOTCH-1, CAT, NRF-2, 18s-rRNA NQO-1,18s-rRNA, HO-1HMOX-1, CAT, SOD-2,
HMOX-2 & GSTM-1) in ARPE-19 Control Cells, Dextromethorphan (Dex 10 & Dex 30µM),
Paraquat (P600 µM) and Dextromethorphan (Dex 10 & Dex 30µM) + Paraquat (P600 µM)
treated ARPE-19 cells was performed. The following anti-oxidant genes were found to
significantly increase upon the treatment of cells with DXM 30µM concomitantly with
Paraquat 600µM: GSTM-1, GCLM, NQO-1, NRF-2, MT-1, HMOX-2, MT-1 and SOD-2.

Figure 3.21 Testing for ARPE-19 protective genes expression (Group2): (HMOX1,

CAT,

SOD-2,

HMOX-2

&

GSTM-1)

in

Dextromethorphan

(D30µM)

&

Dextromethorphan (D30µM) + Paraquat (P600 µM) treated ARPE-19 cells
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22Figure

3.22 Impact of DXM on Protective Genes Expression:(MT-1, NOTCH-1,

CAT, NRF-2, 18s-rRNA NQO-1,18s-rRNA, HO-1HMOX-1, CAT, SOD-2, HMOX-2 &
GSTM-1) in ARPE-19 Control Cells, Dextromethorphan (Dex 10 & Dex 30µM), Paraquat
(P600 µM) and Dextromethorphan (Dex 10 & Dex 30µM), Paraquat (P600 µM) and
Dextromethorphan (Dex 10 & Dex 30µM) + Paraquat (P600 µM) treated ARPE-19 cells.

3.7.5 Testing for Anti-inflammatory genes
Figures (3.23 & 3.24) show ARPE-19 inflammatory genes expression (TNF-a,
MCP-1, IL-18, CCL2, VEGFA & IFN-b) in ARPE-19 Control Cells, Paraquat (P600 µM),
Dextromethorphan (Dex 10 & Dex 30 µM), (Dex 10 & Dex 30 µM) + Paraquat (P600 µM)
treated ARPE-19 cells was performed. The following inflammatory genes were found to
significantly decrease in DXM 30 µM + Paraquat 600µM groups as compared to paraquat
600 µM groups.: TNF-a, MCP-1IL-1B, IFN-b, and IL-17. While there was a noticed
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reduction of the inflammatory genes (IL-6 and IL-8) in the DXM 10 µM + Paraquat 600
µM groups as compared to paraquat 600 µM groups.

23Figure

3.23 Testing for ARPE-19 inflammatory genes expression (TNF-a, MCP-

1, IL-18, CCL2, VEGFA & IFN-b) in ARPE-19 Control Cells & Paraquat (P600 µM) treated
ARPE-19 cells

24Figure

3.24 Impact of DXM on Inflammatory Genes Expression. Genes: (TNF-a,

MCP-1, IL-18, CCL2, & IFN-b) in ARPE-19 Control Cells, Paraquat (P600 µM),
Dextromethorphan (Dex 10 & Dex 30µM), (Dex 10 & Dex 30µM) + Paraquat (P600 µM)
treated ARPE-19 cells
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Chapter 4
Discussion

4.1 Cell Number Titration
There are several options available for measuring cell viability or cell cytotoxicity;
however, the MTT colorimetric assay was chosen for the previous sets of experiments
due to its high throughput screening, reliability, and convenience. MTT assay is widely
used to measure the metabolic activity of cells through MTT reduction by NAD(P)Hdependent cellular oxidoreductase enzyme as an indirect evaluation of cell viability. When
the yellow tetrazolium dye MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide is reduced, it converts to its insoluble form (formazan) that gives a purple color.
An incubation time of 48 hours was selected for all experiments instead of a less nµmber
of hours as in the case of seeding adherent cells, the high seeding densities can delay
cell division, resulting in a decreased metabolic activity. When the cells were allowed to
grow in 48 hours, this gave the room to compare between the metabolic activity of cells
in different groups efficiently with a significant difference in cell viability between the
control groups and the oxidative stress challenged groups by the two reagents (Paraquat
& Hydroquinone) in different doses. The optimum cell number that was selected to seed
ARPE-19 cells in all 96-well plates for MTT assays was 6,000 cells per well as the higher
seeding densities resulted in plateau viability measurements as demonstrated in Figure
3.1.
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4.2 Induction of Oxidative Stress in ARPE-19 Cells
After determining the optimµM ARPE-19 cell seeding density, and optimization of
the oxidative stress-inducing agent dose that can stimulate cell death in ARPE-19 was
important to conduct. The purpose of the experiment was to narrow down the window of
doses of oxidants that can induce 40-60% cell death in cells. The 400 µM of paraquat
resulted in around 30% cell death and the 600 µM concentration resulted in about 50%
cell death; while increasing the reagent’s concentration to 800-1000 µM caused a gradual
decrease of cell death Figure 3.2. The use of hydroquinone as another oxidative stress
agent resulted in about 30% cell death with HQ200 µM and around 50% cell death with
HQ400 µM as seen in Figure 3.6.

4.3 Protection of DXM against Oxidative Stress in ARPE-19 Cells
The results of the MTT assays indicate that treating ARPE-19 cells with DXM
protects ARPE-19 against paraquat and hydroquinone-induced death. As shown in Figure
3.4, the concomitant treatment of DXM with different doses (D1= 10nM, D2= 100 nM, D3=
1µM, D4= 10µM, and D5= 30µM) could protect ARPE-19 cell from oxidative stress that
was induced by Paraquat 400 µM at the same time of treatment. The concomitant
treatment of DXM (10, 20,30 & 50 µM) with Paraquat 600µM on ARPE-19 cells could lead
to cell survival by more than 50% as shown in Figure 3.7. Also, the pre-treatment of
ARPE-19 cells with DXM (10,20,30 &50µM) before inducing cell death by paraquat
600µM could result in around a 30% increase in cell survival as compared to the paraquat
600 µM treated group as seen in Figure 3.7. The post-treatment of ARPE-19 cells with
different doses of DX (10,20,30 &50µM) after inducing cell death by paraquat 600µM
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could also lead to cell survival by around 15 - 25% as compared to the positive controls
in Figure 3.8. In Figure 3.9, the combined treatment of ARPE-19 cells with DXM 10 &30
µM + Hydroquinone (HQ) 200µM shows a higher cell survival as compared to the positive
control; however, DXM 30µM could provide a more significant percentage of cell viability.
The pre-treatment effect of DXM 10 &30 µM (16-18) hours before induction of Oxidative
Stress by Hydroquinone (HQ) 200µM & 400 µM on ARPE-19 cells was shown to protect
cells; and the 10µM dose of DXM could protect against the lower dose of HQ (200µM),
while DXM 30µM showed better protection against the high HQ dose (400µM). In Figure
3.10, the Pre-treatment effect of DXM 10 &30 µM (16-18) hours before induction of
Oxidative Stress by Hydroquinone (HQ) 200µM & 400 µM on ARPE-19 cells could provide
cell protection; nevertheless, there was no protection shown in the condition of the posttreatment of ARPE-19 cells (Figure 3.11) with (DXM 10 &30 µM (4-6) hours after the
induction of Oxidative Stress by Hydroquinone (HQ) 200µM & 400 µM (Left-sided group).
The flow cytometry experiments were chosen for the apoptosis assay measuring the
percent of cell death, and the Fluorochrome-labeled Annexin V protein was chosen as
the binding ligand to the phosphatidylserine (PS), which is normally present intracellularly;
however, in cell death, the cell membrane’s function gets disrupted and the PS is released
to the extracellular environment. Thus, the more colored Annexin V bound cells in the
right quadrants, the higher the number of early and late apoptotic cells. The illustration in
(Figures 3.12, 3.13 & 3.14) shows the flow Cytometry results from a triplicate of samples:
Control [C] Vs. Treatment Groups [Hydroquinone 400µM (Q), DXM 10 &30µM
(D10&D30), DXM 10 & 30µM pre-treatment of cells before oxidative stress induction by
Hydroquinone (DQ10 & DQ30). As shown, the healthy control cells (C1, C2 & C3)
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demonstrated the least apoptotic events, DXM (10 &30µM) were shown to be relatively
safe on cells with minimal apoptotic events, and the groups that were pre-treated with
DXM10 and 30µM showed significantly lower apoptotic events as compared to the
Hydroquinone 400µM treated cells.

4.4 Investigating the Molecular Mechanism of DXM Protection against Oxidative
Stress
Primers quality check, cDNA testing and ARPE-19 cell specificity m-RNA
expression genes were vital experiments to be conducted before heading to the
investigation of the molecular mechanisms of DXM protection in cells. After ensuring that
all the primers to be used in experiments are working efficiently, and all the cDNA of
treatments samples Dextromethorphan (Dex 10 & Dex 30µM), Paraquat (P600 µM), and
Dextromethorphan (Dex 10 & Dex 30µM) + Paraquat (P600 µM) treated ARPE-19 had
the ARPE-19 cell-specific genes (ITGB5, Best-1, Occludin, MERTK-1 & GAPDH) as
compared to the health ARPE-19 control group as shown in (Figures 3.18 & 3.19), all the
other qPCR experiments followed. A testing for ARPE-19 protective genes expression
(MT-1, NOTCH-1, CAT, NRF-2, 18s-rRNA NQO-1,18s-rRNA, HO-1HMOX-1, CAT, SOD2, HMOX-2 & GSTM-1) in ARPE-19 Control Cells, Dextromethorphan (Dex 10 & Dex
30µM), Paraquat (P600 µM) and Dextromethorphan (Dex 10 & Dex 30µM) + Paraquat
(P600 µM) treated ARPE-19 cells was performed. The following anti-oxidant genes were
found to significantly increase upon the treatment of cells with DXM 30µM concomitantly
with Paraquat 600µM: GSTM-1, GCLM, NQO-1, NRF-2, MT-1, HMOX-2, MT-1, and SOD2 as shown in (Figures 3.20, 3.21 & 3.22). Furthermore, testing for ARPE-19 inflammatory
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genes expression (TNF-a, MCP-1, IL-18, CCL2, VEGFA & IFN-b) in ARPE-19 Control
Cells, Paraquat (P600 µM), Dextromethorphan (Dex 10 & Dex 30µM), (Dex 10 & Dex
30µM) + Paraquat (P600 µM) treated ARPE-19 cells was performed. The following
inflammatory genes were found to significantly decrease in DXM 30µM + Paraquat 600µM
groups as compared to paraquat 600µM groups.: TNF-a, MCP-1IL-1B, IFN-b, and IL-17.
While there was a noticed reduction of the inflammatory genes (IL-6 and IL-8) in the DXM
10µM + Paraquat 600µM groups as compared to paraquat 600µM groups as
demonstrated in (Figures 3.23 &3.24).
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Chapter 5
Conclusion

Being the third leading cause of blindness worldwide in aged-people, age-related
macular degeneration (AMD) has been a major challenge for a high quality of life in this
age group. That is in addition to the economic burden of the disease in several countries;
especially, in the U.S. The degeneration of the retinal pigment epithelial cells in the retina,
as well as the cone photoreceptors at the center of the retina, make people blind. While,
there are several unmodifiable risk factors for AMD development, including age, genetics,
and some environmental factors, there are still some modifiable risk factors that can be
moderated such as, the tight control blood glucose level, healthy dieting and exercising,
avoiding the harmful light exposure, and quitting smoking. Furthermore, among the
several pathogenesis mechanisms of developing AMD in the elderly, oxidative stress was
a main component of the disease cycle; nonetheless, developing anti-oxidant strategies
to target reactive oxygen species (ROS) in the retina, bolstering the eye’s natural antioxidant defense against oxidants has the potential to preserve RPE cells and
photoreceptors from death and would successfully reverse AMD. Inhibiting the NMDAmediated Glutamate excitotoxicity in the retina can significantly suppress (ROS)
production in the retina as an active anti-oxidant strategy in limiting the progression of dry
AMD, as well as restricting the inflammatory cascades from progression towards wet
AMD (CNV). Dextromethorphan bromide (DXM) is an NMDA receptor antagonist, which
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is a safe drug that is present in the marketed antitussive formulations. Inhibiting the
activity of NMDA-mediated glutamate overstimulation by DXM has shown promising
results in harnessing the oxidative stress and inflammatory processes in several disease
models such as the brain and retinal ischemia, diabetic retinopathy, atherosclerosis, brain
tumors, seizures, and others, which suggests the worthiness of investigating DSM role in
AMD. Through this study, we were able to investigate the protective role of
Dextromethorphan in protecting RPE against oxidative damage in vitro. The first main
aim was to evaluate the protective ability of the drug on cell viability and apoptotic events
in the presence of two different oxidative stress agents (paraquat & hydroquinone) with
two oxidative stress severity levels. This involved the optimization of cell seeding
densities, oxidants doses, DXM doses, and viability percent & percentage of cell death
measurements through MTT and flow cytometry assays. The second aim was to
investigate the molecular mechanisms underlying DXM protection to cells through PCR
and qPCR analysis. The study findings demonstrated the significant increase of several
anti-oxidant genes in the presence of DXM such as GSTM-1, GCLM, NQO-1, NRF-2, MT1, HMOX-2, MT-1, and SOD-2, and the suppression of several inflammatory genes such
as TNF-a, MCP-1IL-1B, IFN-b, IL-17, IL-6, and IL-8. This would indeed suggest that DXM
can be an invaluable choice for AMD treatment through the mitigation of oxidative stress
in the retinal cells. For future experiments, we will be performing more experiments to
prove this study’s concept by doing protein analysis, and measuring the cell barrier
function in differentiated ARPE-19 cells that express a high number of the original
phenotypes of the primary RPE cells, and finally conducting the in vivo experiments in an
AMD animal model.

54

Chapter 6
References
[1]

J. v. Forrester and H. Xu, “Good news–bad news: the Yin and Yang of immune

privilege

in

the

eye,”

Frontiers

in

Immunology,

vol.

3,

2012,

doi:

10.3389/fimmu.2012.00338.

[2]

B. L. Federman, “The fenestrations of the choriocapillaris in the presence of

choroidal melanoma,” 1982.

[3]

N. H. V. Chong et al., “Decreased Thickness and Integrity of the Macular Elastic

Layer of Bruch’s Membrane Correspond to the Distribution of Lesions Associated with
Age-Related Macular Degeneration,” The American Journal of Pathology, vol. 166, no. 1,
Jan. 2005, doi: 10.1016/S0002-9440(10)62248-1.

[4]

J. Ao, J. P. Wood, G. Chidlow, M. C. Gillies, and R. J. Casson, “Retinal pigment

epitheliµM

in

the

pathogenesis

of

age-related

macular

degeneration

and

photobiomodulation as a potential therapy?,” Clinical & Experimental Ophthalmology, vol.
46, no. 6, Aug. 2018, doi: 10.1111/ceo.13121.

55

[5]

T. Maeda, M. Golczak, and A. Maeda, “Retinal Photodamage Mediated by All-

trans -retinal †,” Photochemistry and Photobiology, vol. 88, no. 6, Nov. 2012, doi:
10.1111/j.1751-1097.2012.01143.x.

[6]

H. Al-Hussaini, J. Hoh Kam, A. Vugler, ayan Semo, and G. Jeffery, “Mature retinal

pigment epitheliµM cells are retained in the cell cycle and proliferate in vivo,” 2008.
[Online]. Available: http://www.molvis.org/molvis/v14/a210.

[7]

M. van Lookeren Campagne, J. LeCouter, B. L. Yaspan, and W. Ye, “Mechanisms

of age-related macular degeneration and therapeutic opportunities,” The Journal of
Pathology, vol. 232, no. 2, Jan. 2014, doi: 10.1002/path.4266.

[8]

P. Mitchell, G. Liew, B. Gopinath, and T. Y. Wong, “Age-related macular

degeneration,” The Lancet, vol. 392, no. 10153, Sep. 2018, doi: 10.1016/S01406736(18)31550-2.

[9]

Y.-C. Tham, X. Li, T. Y. Wong, H. A. Quigley, T. Aung, and C.-Y. Cheng, “Global

Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040,”
Ophthalmology, vol. 121, no. 11, Nov. 2014, doi: 10.1016/j.ophtha.2014.05.013.

[10]

A. Gheorghe, L. Mahdi, and O. Musat,

“AGE-RELATED MACULAR

DEGENERATION,” 2015.

56

[11]

C. Bowes Rickman, S. Farsiu, C. A. Toth, and M. Klingeborn, “Dry Age-Related

Macular Degeneration: Mechanisms, Therapeutic Targets, and Imaging,” Investigative
Opthalmology & Visual Science, vol. 54, no. 14, Dec. 2013, doi: 10.1167/iovs.13-12757.

[12]

A. C. Bird, “Therapeutic targets in age-related macular disease,” Journal of

Clinical Investigation, vol. 120, no. 9, Sep. 2010, doi: 10.1172/JCI42437.

[13]

A. Singh, “Systemic changes in neovascular age-related macular degeneration,”

American Journal of Ophthalmology, vol. 61, no. 6, pp. 193-199.e2, 2014, doi:
10.1016/j.ajo.2012.01.036.

[14]

F. Parmeggiani et al., “Mechanism of Inflammation in Age-Related Macular

Degeneration,” Mediators of Inflammation, vol. 2012, 2012, doi: 10.1155/2012/546786.

[15]

S. Datta, M. Cano, K. Ebrahimi, L. Wang, and J. T. Handa, “The impact of

oxidative stress and inflammation on RPE degeneration in non-neovascular AMD,”
Progress

in

Retinal

and

Eye

Research,

vol.

60,

Sep.

2017,

doi:

10.1016/j.preteyeres.2017.03.002.

[16]

A. G. Casswell, D. Kohen, and A. C. Bird, “Retinal pigment epithelial detachments

in the elderly: classification and outcome.,” British Journal of Ophthalmology, vol. 69, no.
6, Jun. 1985, doi: 10.1136/bjo.69.6.397.

57

[17]

M. Dogru, T. Kojima, C. Simsek, and K. Tsubota, “Potential Role of Oxidative

Stress in Ocular Surface Inflammation and Dry Eye Disease,” Investigative Opthalmology
& Visual Science, vol. 59, no. 14, Nov. 2018, doi: 10.1167/iovs.17-23402.

[18]

Y. Nishimura and H. Hara, “Integrated Approaches to Drug Discovery for

Oxidative Stress-Related Retinal Diseases,” Oxidative Medicine and Cellular Longevity,
vol. 2016, 2016, doi: 10.1155/2016/2370252.

[19]

A. Y. Ting, T. K. Lee, and I. M. MacDonald, “Genetics of age-related macular

degeneration,” Current Opinion in Ophthalmology, vol. 20, no. 5, Sep. 2009, doi:
10.1097/ICU.0b013e32832f8016.

[20]

A. Cheng, C. Pang, A. Leung, J. Chua, D. Fan, and D. Lam, “The association

between cigarette smoking and ocular diseases,” 2000.

[21]

B. R. HAMMOND, B. R. WOOTEN, and D. M. SNODDERLY, “Cigarette Smoking

and Retinal Carotenoids: Implications for Age-related Macular Degeneration,” Vision
Research, vol. 36, no. 18, Sep. 1996, doi: 10.1016/0042-6989(96)00008-9.

[22]

U. Chakravarthy et al., “Clinical risk factors for age-related macular degeneration:

a systematic review and meta-analysis,” BMC Ophthalmology, vol. 10, no. 1, Dec. 2010,
doi: 10.1186/1471-2415-10-31.

58

[23]

S. Kaushik et al., “Dietary glycemic index and the risk of age-related macular

degeneration,” The American Journal of Clinical Nutrition, vol. 88, no. 4, Oct. 2008, doi:
10.1093/ajcn/88.4.1104.

[24]
“Dietary

J. S. L. Tan, J. J. Wang, V. Flood, E. Rochtchina, W. Smith, and P. Mitchell,
Antioxidants

Degeneration,”

and

the

Ophthalmology,

Long-term
vol.

Incidence

115,

no.

of
2,

Age-Related
Feb.

Macular

2008,

doi:

10.1016/j.ophtha.2007.03.083.

[25]

J. Z. Nowak, “Age-related macular degeneration (AMD): pathogenesis and

therapy,” 2006.

[26]

L. S. Lim, P. Mitchell, J. M. Seddon, F. G. Holz, and T. Y. Wong, “Age-related

macular degeneration,” The Lancet, vol. 379, no. 9827, May 2012, doi: 10.1016/S01406736(12)60282-7.

[27]

L. Rohowetz, J. Kraus, and P. Koulen, “Reactive Oxygen Species-Mediated

Damage of Retinal Neurons: Drug Development Targets for Therapies of Chronic
Neurodegeneration of the Retina,” International Journal of Molecular Sciences, vol. 19,
no. 11, Oct. 2018, doi: 10.3390/ijms19113362.

[28]

C. L. Quinlan, I. v. Perevoshchikova, M. Hey-Mogensen, A. L. Orr, and M. D.

Brand, “Sites of reactive oxygen species generation by mitochondria oxidizing different
substrates,” Redox Biology, vol. 1, no. 1, 2013, doi: 10.1016/j.redox.2013.04.005.
59

[29]

C. Grimm, A. Wenzel, T. P. Williams, P. O. Rol, F. Hafezi, and C. E. Remé,

“Rhodopsin-Mediated Blue-Light Damage to the Rat Retina: Effect of Photoreversal of
Bleaching,” 2001.

[30]

Y. Kuse, K. Ogawa, K. TsurµMa, M. Shimazawa, and H. Hara, “Damage of

photoreceptor-derived cells in culture induced by light emitting diode-derived blue light,”
Scientific Reports, vol. 4, no. 1, May 2015, doi: 10.1038/srep05223.

[31]

A. Pizzolla et al., “Reactive Oxygen Species Produced by the NADPH Oxidase 2

Complex in Monocytes Protect Mice from Bacterial Infections,” The Journal of
Immunology, vol. 188, no. 10, May 2012, doi: 10.4049/jimmunol.1103430.

[32]

F. Lacy, D. A. Gough, and G. W. Schmid-Schönbein, “Role of xanthine oxidase

in hydrogen peroxide production,” Free Radical Biology and Medicine, vol. 25, no. 6, Oct.
1998, doi: 10.1016/S0891-5849(98)00154-3.

[33]

B. PU, Y. XUE, Q. WANG, C. HUA, and X. LI, “Dextromethorphan provides

neuroprotection via anti-infammatory and anti-excitotoxicity effects in the cortex following
traµMatic brain injury,” Molecular Medicine Reports, vol. 12, no. 3, Sep. 2015, doi:
10.3892/mmr.2015.3830.

[34]

M. F. Haberecht, C. K. Mitchell, G. J. Lo, and D. A. Redburn, “N-methyl-D-

aspartate-mediated glutamate toxicity in the developing rabbit retina,” Journal of

60

Neuroscience Research, vol. 47, no. 4, Feb. 1997, doi: 10.1002/(SICI)10974547(19970215)47:4<416::AID-JNR7>3.0.CO;2-H.

[35]

Y.-C. Chou, J.-F. Liao, W.-Y. Chang, M.-F. Lin, and C.-F. Chen, “Binding of

dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice,
compared with dextromethorphan and dextrorphan,” Brain Research, vol. 821, no. 2, Mar.
1999, doi: 10.1016/S0006-8993(99)01125-7.

[36]

A. Miller and H. Panitch, “Therapeutic use of dextromethorphan: Key learnings

from treatment of pseudobulbar affect,” Journal of the Neurological Sciences, vol. 259,
no. 1–2, Aug. 2007, doi: 10.1016/j.jns.2006.06.030.

[37]

M. A. DeCoster, K. L. Klette, E. S. Knight, and F. C. Tortella, “Sigma receptor-

mediated neuroprotection against glutamate toxicity in primary rat neuronal cultures,”
Brain Research, vol. 671, no. 1, Feb. 1995, doi: 10.1016/0006-8993(94)01294-R.

[38]

C. L. Carpenter, S. S. Marks, D. L. Watson, and D. A. Greenberg,

“Dextromethorphan and dextrorphan as calciµM channel antagonists,” Brain Research,
vol. 439, no. 1–2, Jan. 1988, doi: 10.1016/0006-8993(88)91497-7.

[39]

J.-H. Song and J. Z. Yeh, “Dextromethorphan inhibition of voltage-gated proton

currents in BV2 microglial cells,” Neuroscience Letters, vol. 516, no. 1, May 2012, doi:
10.1016/j.neulet.2012.03.065.

61

[40]

E.-J. Shin et al., “Neuropsychotoxic and Neuroprotective Potentials of

Dextromethorphan and Its Analogs,” Journal of Pharmacological Sciences, vol. 116, no.
2, 2011, doi: 10.1254/jphs.11R02CR.

[41]

S. A. Mousavi, M. Saadatnia, F. Khorvash, T. Hoseini, and P. Sariaslani,

“Evaluation of the neuroprotective effect of dextromethorphan in the acute phase of
ischaemic

stroke,”

Archives

of

Medical

Science,

vol.

3,

2011,

doi:

10.5114/aoms.2011.23413.

[42]

S.-L. Liu et al., “Dextromethorphan reduces oxidative stress and inhibits

atherosclerosis and neointima formation in mice,” Cardiovascular Research, vol. 82, no.
1, Jan. 2009, doi: 10.1093/cvr/cvp043.

[43]

W. Zhang et al., “Neuroprotective effect of dextromethorphan in the MPTP

Parkinson’s disease model: role of NADPH oxidase,” The FASEB Journal, vol. 18, no. 3,
Mar. 2004, doi: 10.1096/fj.03-0983fje.

[44]

P.-Y. LIU et al., “Treatment with dextromethorphan improves endothelial function,

inflammation and oxidative stress in male heavy smokers,” Journal of Thrombosis and
Haemostasis, vol. 6, no. 10, Oct. 2008, doi: 10.1111/j.1538-7836.2008.03082.x.

[45]

X. Xu et al., “Prevention of Hippocampal Neuronal Damage and Cognitive

Function Deficits in Vascular Dementia by Dextromethorphan,” Molecular Neurobiology,
vol. 53, no. 5, Jul. 2016, doi: 10.1007/s12035-016-9786-5.
62

[46]

M. Keller et al., “Dextromethorphan is protective against sensitized N-methyl-d-

aspartate receptor-mediated excitotoxic brain damage in the developing mouse brain,”
European Journal of Neuroscience, vol. 27, no. 4, Feb. 2008, doi: 10.1111/j.14609568.2008.06062.x.

[47]

B. R. Brooks et al., “Treatment of pseudobulbar affect in ALS with

dextromethorphan/quinidine: A randomized trial,” Neurology, vol. 63, no. 8, Oct. 2004,
doi: 10.1212/01.WNL.0000142042.50528.2F.

[48]

H. S. Panitch et al., “Randomized, controlled trial of dextromethorphan/quinidine

for pseudobulbar affect in multiple sclerosis,” Annals of Neurology, vol. 59, no. 5, May
2006, doi: 10.1002/ana.20828.

[49]

E. P. Pioro et al., “Dextromethorphan Plus Ultra Low-Dose Quinidine Reduces

Pseudobulbar Affect,” Annals of Neurology, vol. 68, no. 5, Nov. 2010, doi:
10.1002/ana.22093.

[50]

G. H. Bresnick, “Excitotoxins: A Possible New Mechanism for the Pathogenesis

of Ischemic Retinal Damage,” Archives of Ophthalmology, vol. 107, no. 3, Mar. 1989, doi:
10.1001/archopht.1989.01070010349021.

[51]

C. Brandon and D. M. Lam, “L-glutamic acid: a neurotransmitter candidate for

cone photoreceptors in hµMan and rat retinas.,” Proceedings of the National Academy of
Sciences, vol. 80, no. 16, Aug. 1983, doi: 10.1073/pnas.80.16.5117.
63

[52]

Y. H. Yoon, “Dextromethorphan Protects Retina Against Ischemic Injury In Vivo,”

Archives

of

Ophthalmology,

vol.

107,

no.

3,

Mar.

1989,

doi:

10.1001/archopht.1989.01070010419037.

64

